2016-07-19T12:54:09-05:00 2015-12-31 BDO USA LLP 8401 GREENSBORO DRIVE 8TH FLOOR MCLEAN VA 22102 990 2015-01-01 311621592 INTERNATIONAL VACCINE INSTITUTE % SEUNGHWA CHEON INTE 8228722803 snu research park 1 gwanak-ro seoul KS 151-742 PILLIP DRIVER DEP DIR OF FIN & OP 7038930600 2016-07-18 true Jeffrey J Schragg P00234543 7038930600 2016-07-18 2015 2016-09-27 15:27:22Z JEROME H KIM SNU RESEARCH PARK 1 GWANAK-RO SEOUL KS 151-742 21157422 false X www.ivi.int X 1997 IVI's mission is to discover, develop and deliver safe, effective DELIVER SAFE, EFFECTIVE AND AFFORDABLE VACCINES FOR THE WORLD'S DEVELOPING NATIONS. 10 9 0 6 0 23508996 21104491 0 0 72912 35005 21353 12547 23603261 21152043 7574634 4455317 0 0 9598354 9053946 0 0 825991 7886585 8319983 25059573 21829246 -1456312 -677203 29405974 28657279 24513481 24922927 4892493 3734352 X IVI'S MISSION IS TO DISCOVER, DEVELOP AND DELIVER SAFE, EFFECTIVE AND AFFORDABLE VACCINES FOR THE WORLD'S DEVELOPING NATIONS. ITS VISION IS DEVELOPING COUNTRIES FREE OF SUFFERING FROM INFECTIOUS DISEASE. true true 4005864 2169518 The Dengue Vaccine Initiative (DVI) has been paving the way for introduction of dengue vaccine through evidence generation, policy and access, regulatory, and advocacy activities. DVI has been conducting studies on dengue disease and economic burden through field studies in Thailand, Vietnam, Cambodia, Colombia, Burkina Faso, and Gabon. In 2015, DVI continued surveillance, serological surveys, and cost-of-illness survey in these countries. In addition, DVI made preparations for the launch of a new field site in Kenya. DVI convened the Americas Dengue Prevention Board Meeting in 2015 in Colombia. The meeting focused on providing technical consultation to policy makers and key stakeholders for dengue vaccine introduction in Latin America. In Nov 2015, DVI convened a meeting of national regulatory authorities (NRAs) from dengue endemic countries to provide technical consultation and discuss the status of regulatory approvals for dengue vaccine. 2042858 497627 Typhoid Surveillance in sub-Saharan Africa Program: TSAP aims to generate data on the burden of typhoid fever and other invasive Salmonella infections in Africa through standardized surveillance and disease burden studies among a network of 10 African countries. Comparable and contemporary population-based data on Salmonella spp. Infections in sub-Saharan Africa (sSA) are lacking and data, collected systematically, are urgently needed to make evidence-based decisions on the introduction of existent and upcoming vaccines against typhoid (TF)/paratyphoid fever, and non-typhoidal Salmonella (NTS) infections. The Typhoid Fever Surveillance in Africa Program (TSAP), started in 2010 and developed by the International Vaccine Institute, aims to close the data gap on invasive Salmonella infections between African and Asian countries. Accordingly, systematic and standardized passive surveillance and diagnostics of febrile patients by haemoculture were established at various sites in sSA. Since results are harmonized across study sites, incidences are comparable across. Secondary outcomes of TSAP include evaluation of antimicrobial resistance patterns and the identification of carriers of Salmonella spp. Participating countries are Guinea Bissau, Senegal, Burkina Faso, Ghana, Sudan, Ethiopia, Kenya, Tanzania, Madagascar, and South Africa. In 2013, nine of the ten TSAP sites completed surveillance activities; the site in Ethiopia completed activities in January 2014. All sites are closed. Preliminary incidence data have been presented at different international conferences (i.e. Vaccines for Enteric Diseases (VED), Bangkok, Nov 2013; American Society for Tropical Medicine and Hygiene (ASTMH), Washington DC, Nov 2013). Blood specimen are currently being investigated further at the Sanger Institute in Cambridge, UK to determine strain relatedness and molecular drug resistance paramenters. The Bill and Melinda Gates Foundation awarded a follow-up grant at the end 2013. The purpose of this new grant is to: (1) develop and validate a risk and typhoid burden prediction model for sub-Saharan Africa, (2) investigate and define the incidence of typhoid fever in four sites in sub-Saharan Africa selected using the model, and (3) assess water quality at the African sites. Following the completed surveillance in all 13 TSAP sites in 10 countries, the data cleaning and analysis is conducted in 2015. As a result, 15 TSAP papers are published in CID. The shipping process of all TSAP samples also started. They will be kept in IVI for further tests. 1355903 750000 Cholera OCV: The studys objective is to evaluate the efficacy and safety of a single dose regimen of the modified killed oral cholera vaccine. An individually randomized, placebo controlled trial to measure single dose efficacy was initiated in January 2014. The vaccine efficacy of six-month follow-up was 40% against all cholera and 63% against severely dehydrated cholera. The paper of six-month follow-up has been published by the New England Journal of Medicine in May 2016*. The follow up for one year and its data analysis have been completed in 2015 and the manuscript of one-year data is preparing. Surveillance continues to complete 2 years of follow-up. 9229515 1038172 16634140 true true false false false false false false false false true false false false true false true false false true true true false false false false false true false true false false false true false false false false false false false false false false false false false true X 0 0 0 false true KS false false false false false false false false X 10 9 true false false false false true false true true false false false true true true true true true true false X SEUNGHWA CHEON 8228722801 snu research park 1 gwanak-ro gwanak-gu, seoul KS 151-742 Adel AF Mahmoud Chairman / Board of Trustee 1.0 0.0 X 1638 0 0 George Bickerstaff Director / Board of Trustee 1.0 0.0 X 1684 0 0 Juhani Eskola Director / Board of Trustee 1.0 0.0 X 796 0 0 Romulo Garcia Director / Board of Trustee 1.0 0.0 X 842 0 0 Joseph Kim Director / Board of Trustee 1.0 0.0 X 1592 0 0 George Siber Director / Board of Trustee 1.0 0.0 X 1684 0 0 Fred Binka Director / Board of Trustee 1.0 0.0 X 934 0 0 Yoo Dae Jong Director / Board of Trustee 1.0 0.0 X 1500 0 0 Jerome Kim Director General 40.0 0.0 X X 338523 0 51274 Laura Digilio Deputy Director General of Dev 40.0 0.0 X 175073 0 14349 Deborah Gene Hong Head of the Communications and 40.0 0.0 X 156083 0 25567 John Morahan Deputy Director General of Fin 40.0 0.0 X 253514 0 28788 In Kyu Yoon Deputy Director General of Sci 40.0 0.0 X 102881 0 17921 Rodney Carbis Head, Vaccine Development Depa 40.0 0.0 X 203762 0 12294 Manki Song Senior Research Scientist 40.0 0.0 X 151950 0 25707 Sudeep Kothari Research Scientist 40.0 0.0 X 139484 0 20396 Vinay Kumar Gupta Chief, IT Team 40.0 0.0 X 134874 0 22124 Sushant Sahastrabuddhe Program Leader of EDD and Head 40.0 0.0 X 126060 0 22562 1792874 0 240982 10 false true false The Boston Consulting Group Inc PO box 75200 CHICAGO IL 606755200 CONSULTING 1439578 Spencer Stuart PO Box 98991 CHICAGO IL 98991 HR RECRUITING 110503 2 44483 4370748 16689260 18669 21104491 0 35005 35005 0 0 0 0 0 0 0 0 2067 5379 -3312 -3312 MISCELLANEOUS REVENUE 900099 15859 15859 15859 21152043 -3312 50864 711632 711632 0 3743685 3743685 0 1762057 1036440 543968 181649 0 5914115 3314923 2323845 275347 774814 286430 444390 43994 464603 202012 248694 13897 138357 65592 63110 9655 0 59865 20609 38772 484 58060 58060 0 0 0 2720262 2208063 257395 254804 0 168298 103946 49057 15295 222886 185260 36977 649 0 1560228 1560228 1389378 1231521 145690 12167 0 238621 173394 62380 2847 0 0 237281 101068 136213 76147 45200 30947 LAB SUPPLIES 1438863 1360204 78659 TRAINING 32146 15529 13857 2760 REPAIRS AND MAITENANCE 80306 24390 55883 33 ALLOCATION OF INDIRECT COSTS 1796144 -1796144 37642 8098 17134 12410 21829246 16634140 4369115 825991 0 0 27781458 26528150 224236 343578 4245 8171 95591 113417 0 0 248236 204658 0 0 289794 369155 7541816 6455913 757723 1085903 0 0 0 0 0 0 0 0 4691 4247 29405974 28657279 907849 1843335 0 0 23604225 23079592 0 0 0 0 0 0 0 0 0 0 1407 0 24513481 24922927 X 2180331 1022190 2712162 2712162 0 0 4892493 3734352 29405974 28657279 X -677203 -480938 X X false true X true false X 24807120 17686547 19680492 23508996 21104491 106787646 0 0 24807120 17686547 19680492 23508996 21104491 106787646 43873413 62914233 524915 231655 8163 72912 35005 872650 0 89771 89690 13778 28581 15859 237679 107897975 8430 0.58309 0.62363 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 7467931 6385260 1082671 73885 70653 3232 1085903 0 0 21157421 21157421 -5378 -5378 21152043 21834624 5378 5378 21829246 21829246 Part XI, Line 4B: Cost of Goods Sold -5,378 Part XII, Line 2D: Cost of Goods Sold 5,378 true East Asia and the Pacific 1 126 Program Services Program Service 13466243 East Asia and the Pacific Grantmaking 1809253 Europe (Including Iceland and Greenland) Grantmaking 30655 South America Grantmaking 161107 South Asia Grantmaking 972297 Sub-Saharan Africa Grantmaking 770374 1 126 1 126 17209929 17209929 Sub-Saharan Africa PROGRAM SERVICE 28879 WIRE South Asia PROGRAM SERVICE 6384 WIRE South Asia PROGRAM SERVICE 21702 WIRE Sub-Saharan Africa PROGRAM SERVICE 78392 WIRE Sub-Saharan Africa PROGRAM SERVICE 40000 WIRE East Asia and the Pacific PROGRAM SERVICE 6072 WIRE East Asia and the Pacific PROGRAM SERVICE 53832 WIRE South Asia PROGRAM SERVICE 90000 WIRE Sub-Saharan Africa PROGRAM SERVICE 85000 WIRE South Asia PROGRAM SERVICE 22650 WIRE South Asia PROGRAM SERVICE 750000 WIRE Europe (Including Iceland and Greenland) PROGRAM SERVICE 26918 WIRE South Asia PROGRAM SERVICE 50000 WIRE East Asia and the Pacific PROGRAM SERVICE 387000 WIRE Sub-Saharan Africa PROGRAM SERVICE 278309 WIRE South America PROGRAM SERVICE 49900 WIRE East Asia and the Pacific PROGRAM SERVICE 405500 WIRE South Asia PROGRAM SERVICE 31561 WIRE East Asia and the Pacific PROGRAM SERVICE 180000 WIRE East Asia and the Pacific PROGRAM SERVICE 13350 WIRE Sub-Saharan Africa PROGRAM SERVICE 13088 WIRE East Asia and the Pacific PROGRAM SERVICE 400000 WIRE South America program services 6915 WIRE Sub-Saharan Africa program service 42035 WIRE South America PROGRAM SERVICE 104292 WIRE Sub-Saharan Africa PROGRAM SERVICE 200466 WIRE East Asia and the Pacific PROGRAM SERVICE 5134 WIRE East Asia and the Pacific PROGRAM SERVICE 358366 WIRE 28 false false false false false false MONITORING GRANTS OUTSIDE THE US THE IVI IS LOCATED IN SEOUL, KOREA WHERE ALL THE GRANT FUNDS ARE MANAGED AND EXECUTED. THE IVI HAS IN PLACE A VERY DETAILED AND RIGOROUS SYSTEM OF FINANCIAL MONITORING. THIS SYSTEM, WHICH IS EVALUATED BY INTERNAL FINANCE PERSONNEL THROUGHOUT THE YEAR AND AUDITED EXTERNALLY EVERY YEAR, IS USED IN CONJUNCTION WITH CAREFUL PROJECT DEVELOPMENT AND IMPLEMENTATION TO ENSURE ACCOUNTABILITY AND BUDGETARY MANAGEMENT RESPONSIBILITY. FOR SUBGRANTS, THE IVI HAS A BROAD OVERALL SYSTEM OF REVIEWING AND TRACKING THE USE OF GRANTS, AND MORE SPECIFIC DAY-To-DAY REVIEW PROCESSES, WHICH INCLUDE THE FOLLOWING: -REVIEWS OF FINANCIAL AND NARRATIVE REPORTS, AUDIT REPORTS, CORRESPONDENCE AND OTHER DOCUMENTATION PROVIDED BY THE GRANTEES -DIRECT COMMUNICATION WITH GRANTEES THROUGH TELEPHONE AND EMAIL FOR QUESTIONS AND TO CHECK ON PROGRESS OF THE PROJECT -ON-SITE VISITS TO THE FIELD SITES TO REVIEW ONE OR MORE ASPECTS OF THE PROJECTS -MONITORING THROUGH AN EXTERNAL AUDIT. A CERTAIN NUMBER OF SUB-GRANTEES ARE SELECTED FOR THE AUDIT EACH YEAR, WHICH IS DONE TO ENSURE FINANCIAL AND EXPENDITURE COMPLIANCE WITH THE RESEARCH AGREEMENT. true Innovations for Global Health 3240 Huron Peak Ave Lee Kendall Superior CO 80027 201059464 501(C)(3) 181894 PROGRAM SERVICE THE JOHNS HOPKINS UNIVERSITY 3400 NORTH CHARLES ST BALTIMORE MA 21218 520595110 501(C)(3) 160302 PROGRAM SERVICE UNIVERSITY OF FLORIDA BOARD OF TRUSTEES 123 TIGERT HALL GAINSVILLE FL 32611 590974739 501(C)(3) 94295 PROGRAM SERVICE CHARLES RIVER LABORATORIES INC 251 Ballardvale St Wilmington MA 01887 75700 PROGRAM SERVICE JSI RESEARCH&TRAINING INSTITUTE INC 44 FARNSWORTH ST BOSTON MA 02210 042679824 501(C)(3) 51423 PROGRAM SERVICE THE ALBERT BSABIN VACCINE INSTITUTE 2000 PENN AVE NW WASHINGTON DC 20006 061389829 501(C)(3) 46000 PROGRAM SERVICE FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVE NORTH SEATTLE WA 98109 237156071 501(C)(3) 45140 PROGRAM SERVICE UNIVERSITY OF WISCONSIN FOUNDATION 1848 UNIVERSITY AVENUE MADISON WI 53706 390743975 501(C)(3) 22619 PROGRAM SERVICE GLOBAL SOLUTIONS FOR INFECTIOUS DISEASE 830 DUBUQUE AVENUE South San Francisco CA 94080 200941177 501(C)(3) 17600 PROGRAM SERVICE INC RESEARCH LLC 3201 Beechleaf Court STE 600 Raleigh NC 27604 9860 PROGRAM SERVICE BIOQUAL INC 4 Research Court Rockville MD 20850 6798 PROGRAM SERVICE 8 3 MONITORING USE OF GRANTS THE IVI IS LOCATED IN SEOUL, KOREA WHERE ALL THE GRANT FUNDS ARE MANAGED AND EXECUTED. THE IVI HAS IN PLACE A VERY DETAILED AND RIGOROUS SYSTEM OF FINANCIAL MONITORING. THIS SYSTEM, WHICH IS EVALUATED BY INTERNAL FINANCE PERSONNEL THROUGHOUT THE YEAR AND AUDITED EXTERNALLY EVERY YEAR, IS USED IN CONJUNCTION WITH CAREFUL PROJECT DEVELOPMENT AND IMPLEMENTATION TO ENSURE ACCOUNTABILITY AND BUDGETARY MANAGEMENT RESPONSIBILITY. FOR SUBGRANTS, THE IVI HAS A BROAD OVERALL SYSTEM OF REVIEWING AND TRACKING THE USE OF GRANTS, AND MORE SPECIFIC DAY-To-DAY REVIEW PROCESSES, WHICH INCLUDE THE FOLLOWING: -REVIEWS OF FINANCIAL AND NARRATIVE REPORTS, AUDIT REPORTS, CORRESPONDENCE AND OTHER DOCUMENTATION PROVIDED BY THE GRANTEES -DIRECT COMMUNICATION WITH GRANTEES THROUGH TELEPHONE AND EMAIL FOR QUESTIONS AND TO CHECK ON PROGRESS OF THE PROJECT -ON-SITE VISITS TO THE FIELD SITES TO REVIEW ONE OR MORE ASPECTS OF THE PROJECTS -MONITORING THROUGH AN EXTERNAL AUDIT. A CERTAIN NUMBER OF SUB-GRANTEES ARE SELECTED FOR THE AUDIT EACH YEAR, WHICH IS DONE TO ENSURE FINANCIAL AND EXPENDITURE COMPLIANCE WITH THE RESEARCH AGREEMENT. X X X X true true X X X false false false false false false false false false Jerome Kim Director General 250000 0 0 0 88523 0 37500 0 13774 0 389797 0 0 0 Laura Digilio Deputy Director General of Dev 153333 0 0 0 21740 0 7250 0 7099 0 189422 0 0 0 Deborah Gene Hong Head of the Communications and 131372 0 0 0 24711 0 19706 0 5861 0 181650 0 0 0 John Morahan Deputy Director General of Fin 160521 0 52937 0 40056 0 20620 0 8168 0 282302 0 0 0 Rodney Carbis Head, Vaccine Development Depa 195066 0 0 0 8696 0 4209 0 8085 0 216056 0 0 0 Manki Song Senior Research Scientist 148040 0 0 0 3910 0 22075 0 3632 0 177657 0 0 0 Sudeep Kothari Research Scientist 83559 0 0 0 55925 0 12534 0 7862 0 159880 0 0 0 Vinay Kumar Gupta Chief, IT Team 93390 0 0 0 41484 0 14009 0 8115 0 156998 0 0 0 COMPENSATION TRAVEL FOR COMPANION: After 15 months of service, the internationally recruited staff is entitled to home leave travel. This entitlement is an economy round trip between duty station and home base for staff, spouse and dependents under 21. TAX INDEMNIFICATION AND GROSS UP PAYMENTS: IN ORDER TO EQUALIZE THE BENEFITS ACCRUED TO INtERNATIONALLY RECRUITED STAFF, IVI COMPENSATES STAFF WHO ARE OBLIGATED TO PAY TAXES ON IVI DERIVED INCOME TO THEIR HOME COUNTRY. ANY TAX SUBSEQUENTLY LEVIED ON THE AMOUNT OF THE REIMBURSEMENT IS NOT REIMBURSED. HOUSING ALLOWANCE: IVI PROVIDES INTERNATIONALLY RECRUITED STAFF IN KOREA WITH A HOUSING ALLOWANCE UP TO 75% OF A CEILING THAT IS ESTABLISHED AND REVIEWED PERIODICALLY. PERSONAL SERVICES (I.E. driver): IVI PROVIDES THE DIRECTOR GENERAL WITH A DRIVER WHICH is INCLUDED IN HIS/HER EMPLOYMENT CONTRACT PACKAGE APPROVED BY THE BOARD OF TRUSTEES. JEROME KIM EMPLOYEE EDUCATION X 19005 6325 false true true LAURA DIGILIO EMPLOYEE HOUSING LOAN X 27264 27264 false true true DEBORAH GENE HONG EMPLOYEE HOUSING LOAN X 26714 26714 false true true IN-KYU YOON EMPLOYEE HOUSING LOAN X 11894 4821 false true true IN-KYU YOON EMPLOYEE EDUCATION X 6694 3905 false true true SUDEEP KOTHARI EMPLOYEE HOUSING LOAN X 27375 27375 false true true SUDEEP KOTHARI EMPLOYEE EDUCATION X 8983 5240 false true true VINAY KUMAR GUPTA EMPLOYEE HOUSING LOAN X 3167 3167 false true true VINAY KUMAR GUPTA EMPLOYEE EDUCATION X 6415 2127 false true true SUSHANT SAHASTRABUDDHE EMPLOYEE HOUSING X 8873 6479 false true true 113417 FORM 990, PART III, LINE 2 LINE 2 - NEW PROGRAM SERVICE ACCOMPLISHEMENTS: 'Vi-DT clinical development support for SK' is to accelerate the clinical development and licensure of a safe, efficacious, and affordable new typhoid conjugate vaccine. VI-DT vaccine has been developed by IVI Process Development team under VIVA (Vi based Vaccines in Asia, 2007-2014). Vi-DT technology has bed transferred to SK Chemicals under VIVA grant and cooperative agreement for Vi-DT early clinical development has been signed by SK chemicals and IVI in 2015. FORM 990, PART III, LINE 3 VIVA Initiative aims to reduce mortality and morbidity due to typhoid fever in developing countries through the acceleration of the adoption of Vi vaccine, and the development, testing, and licensure of affordable next-generation Vi-conjugate vaccines. From September 2007 to May 2015, to ensure a cost-competitive supply of Vi polysaccharide(Vi) vaccine for introduction in high-risk, typhoid-endemic areas, and for subsequent production of typhoid conjugate vaccines, IVI completed product development and transfer of production technology of Vi vaccine, and conducted clinical trials for licensure and ensure WHO prequalification. IVI implemented pilot Vi introduction projects in Kathmandu, Nepal and Karachi and assessed the Vi vaccine introduction campaigns in each site in terms of programmatic feasibility, population demand(coverage), financial sustainability and impacted on clinical disease. To pave the way for the introduction of typhoid vaccines immunization programs of developing countries, IVI develop an investment case for GAVI alliance funding and implement advocacy strategy and development partnerships at the country, regional, and global level. FORM 990, PART III, LINE 4D VACCINE RESEARCH AND DEVELOPMENT FORM 990, PART V, LINES 1A AND 2A IVI'S HEADQUARTERS IS BASED IN SEOUL, KOREA. SINCE THE ORGANIZATION IS NOT U.S. BASED, THEY ARE NOT REQUIRED TO FILE W-2'S OR 1099'S. AS OF DECEMBER 31, 2015, THE ORGANIZATION REPORTS 126 EMPLOYEES. FORM 990, PART V, LINE 4 IVI is a foreign organization. It is not required to file Form FinCEN 114 (Report of Foreign Bank and Financial Accounts). FORM 990, PART VI, LINE 2 Adel Mahmoud is a Board member of Inovio Pharmaceuticals where Joseph Kim is a CEO & President at. They are both members of IVI Board of Trustees. FORM 990, PART VI, LINE 7A Director General of the Institute is also a voting member of the Board; thus, he/she can participate in the election of the Board. FORM 990, PART VI, LINE 11B The finance team makes a first draft of Form 990 and the related schedules. HR provides Specific information on compensation and other teams provide fundraising, governance and management information. The CFO and Senior finance manager review all of the forms and schedules and check them for accuracy of the financial information. The reviewed draft is sent to members of the Board of Trustees (BOT) Finance Committee, which is composed of 5 BOT members, plus the BOT Chairman and IVI Director General. The PDF file of the draft is sent to each member via electronic mail. Normally we give them 2 weeks for their review, and their comments and questions are received and addressed accordingly. FORM 990, PART VI, LINE 12C The IVI HR provides a copy of the conflict of interest policy to all directors, officers and staff to complete annually. Not only persons with actual or potential conflicts of interest but also persons who do not have any conflicts of interest must submit a signed copy of the disclosure of actual or potential conflicts of interest to the IVI Board Secretariat or the IVI Human Resources Unit as appropriate. The Conflict Coordinator (Director General) creates a Conflict Committee composed of three other members of the IVI staff to review conflict of interest issues that may arise. The Conflict Committee shall be responsible for ensuring that relevant conflicts of interest, and the procedures taken to eliminate, reduce or manage those conflicts, are disclosed at or prior to any Board of Trustees meeting. The Committee shall keep a record of all actual and potential conflicts of interest and report annually thereon to the Board of Trustees. In case of trustees, IVI Board secretariat provides a copy of the conflict of interest policy to the members when they first join, all members must submit a signed copy of the disclosure of actual and potential conflicts of interest to IVI. The members should report their changes of status to the Board Secretariat. FORM 990, PART VI, LINE 15A and 15B THE IVI UNDERTAKES A COMPREHENSIVE COMPENSATION STUDY FOR ITS OFFICERS AND KEY EMPLOYEES. A COMPENSATION CONSULTANT CONDUCTS THE STUDY AND LOOKS AT COMPENSATION AMONG COMPARABLE ORGANIZATIONS WITH SIMILAR POSITIONS AND RESPONSIBILITIES IN ORDER TO PROVIDE MARKET DATA TO DETERMINE IVI STAFF MEMBER COMPENSATION. COMPENSATION IS SET BY INDEPENDENT PERSONS, AND CONTEMPORANEOUS DOCUMENTATION OF THE PROCESS IS RETAINED. FORM 990, PART VI, LINE 19 The IVI's governing documents-Establishment Agreement, Headquarters Agreement, Constitution and Amendments to the Constitution are available on IVI's website. The Summary of financial report is included in IVI's Annual report. FORM 990, PART XI, LINE 9 FOREIGN CURRENCY EXCHANGE LOSS -480,939 FORM 990 PART IX LINE 11G DESCRIPTION:CONTRACTED CONSULTANT TOTAL FEES:2170752 FORM 990 PART IX LINE 11G DESCRIPTION:RECRUITMENT TOTAL FEES:246161 FORM 990 PART IX LINE 11G DESCRIPTION:OTHERS TOTAL FEES:303349